Gene Drug Therapy for Myocardial Infarction

The gene drug therapy can treat myocardial infarction.
Reporter recently learned from the United Nations International Center for Genetic Engineering and Biotechnology (ICGEB) that its research team has developed a new type of therapy, which can help to induce cardiac cell regeneration and treat heart failure by implanting gene drugs. Myocardial infarction is a kind of coronary heart disease with coronary atherosclerosis. The sudden obstruction of coronary artery leads to ischemia and necrosis of myocardial cells. Permanent structural damage of myocardial infarction site increases the risk of heart failure, which is very serious and can directly cause death. According to the World Health Organization, the disease has affected more than 23 million people in the world.
This is the first experiment to prove that heart regeneration can be achieved by implanting effective gene drugs. The drug stimulates heart regeneration in large animals, which has the same cardiac structure and physiological functions as humans. According to Professor Maro Gaka, the first author of the article and head of the research team, the experiment used a virus to deliver microRNA molecules to infarcted heart cells. In large mammals, cardiac repair can be achieved by strictly controlling therapeutic agents to stimulate the proliferation of endogenous cardiomyocytes. But at present, the dosage and time of administration can not be effectively controlled. In the long run, adverse reactions will occur. Gaca added: "Although we know that this works well in mice, clinical trials in large mammals will take a while to proceed, and we need to learn how to manage RNA as a synthetic molecule in large animals and patients."
Gaka said: “This is a very exciting moment. After several failed attempts to regenerate the heart with stem cells, we first saw real heart repair. The study was completed by ICGEB in collaboration with the Santa Ana Institute of Higher Education in Italy and the Monastario Foundation Hospital. ”
Looking for chemical products? Let suppliers reach out to you!
2026-07-16
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
6th Drug Safety Symposium 2026 to Focus on “Beyond Algorithms & Assumptions, What Actually Matters in Pharmacovigilance”
-
Soybean rust resistance gene was cloned in Chinese Academy of Agricultural Sciences
-
The European Parliament has passed a gene-editing bill to further loosen regulations on gene-edited crops
-
Roche Acquires Carmot for $3.1 Billion to Enter Obesity Drug Market
-
Discovery of a Potential new target for ALS Drugs to curb protein misfolding!
-
Two departments issued a document to guidethe strengthening of drug cases investigation and handling
-
National Health Care Commission: 50% of thecountry's public hospitals above the second level have carried out appointmentdiagnosis and treatment services
-
India starts testing a pharmaceuticalcompany's exports of cough syrup
-
Inmanar Announces Several BreakthroughSequencing Innovations
-
China's medical supplies supply securitycapabilities continue to enhance
Recommend Reading
-
Novartis Boosts 2025 Earnings Forecast as US Tariff Risks Loom $23 Billion Investment and $10 Billion Buyback Unveiled
-
Zydus Lifesciences Blocked by Delhi High Court in Cancer Biosimilar Case $9.3 Billion Opdyta Patent Dispute Intensifies
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
-
Cost Support and Tightening Supply Fuel March Toluene Market Rally
-
This Week's Aniline Market Stabilizes in China (5.4-5.8)
-
After Reaching a High, Polyester Chip Prices in May Showed Wide Fluctuations at High Levels in China
-
Business Society: Both Supply and Demand Weak, Costs Hard to Sustain—Bisphenol A Set for Volatile Decline in 2025
-
Low Levels Across the Entire Cycle + Widening Negative Deviation—Melamine Short-Term Market Weakens